Paper Details

  1. Home
  2. Paper Details

Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.

Author: Ben-HorinShomron, ChenMin-Hu, ChowersYehuda, ColombelJean Frederic, GuoJing, HibiToshifumi, KaplanGilaad G, KobayashiTaku, MaoRen, NovackLena, Peyrin-BirouletLaurent, SergienkoRuslan, ZhangJian, ZhaoYue

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Biologic treatment for Crohn's disease (CD) was equally effective for patients with short-duration (≤18 months) and long-duration disease (>18 months). In ulcerative colitis (UC), there was no difference in effectiveness based on disease duration.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIMS: Starting biologic treatment early in the course of inflammatory bowel disease (IBD) may be associated with higher efficacy, especially in Crohn's disease (CD). METHODS: This was a systematic review and individual-patient data meta-analysis of all placebo-controlled trials of bi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/j.gastro.2021.10.037

データ提供：米国国立医学図書館（NLM）

Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease

This comprehensive systematic review and individual-patient data meta-analysis delves into the effectiveness of biologic drugs in treating inflammatory bowel disease (IBD), particularly Crohn's disease (CD). The study investigates whether the efficacy of biologics differs based on the duration of the disease, analyzing data from 25 placebo-controlled trials. The study found that remission induction rates were higher in patients with short-duration CD compared to those with longer disease duration. However, the proportional biologic/placebo treatment effect on induction of remission was similar across disease durations.

Biologic Drugs for IBD: Early Intervention Shows Promise

The study reveals intriguing insights into the effectiveness of biologic drugs for IBD, particularly in the context of early intervention. While the study found higher remission rates in patients with shorter disease durations, the overall treatment effect remained consistent across different disease stages. This suggests that biologic drugs may be beneficial regardless of the duration of the disease. The results are similar to finding a hidden oasis in a vast desert: a promising outcome for those seeking relief from IBD.

Navigating the Desert of Inflammatory Bowel Disease

The study's findings provide valuable information for patients and clinicians navigating the complex terrain of inflammatory bowel disease (IBD). The study suggests that early intervention with biologic drugs may offer a path to remission, regardless of the duration of the disease. Like a skilled navigator in the desert, understanding the nuances of IBD treatment can lead to improved outcomes and a more manageable journey.

Dr.Camel's Conclusion

The study suggests that biologic drugs can be an effective treatment option for IBD, regardless of the duration of the disease. The findings highlight the potential benefits of early intervention and emphasize the importance of individualized treatment approaches to optimize patient outcomes.

Date :
  1. Date Completed 2022-02-22
  2. Date Revised 2022-02-22
Further Info :

Pubmed ID

34757139

DOI: Digital Object Identifier

10.1053/j.gastro.2021.10.037

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.